Frank Aquila, global head of S&C’s M&A practice, has been named a “Healthcare Law Trailblazer” by The National Law Journal. The Trailblazers series spotlights lawyers who are recognized as agents of change.
Over the course of his career, Frank has advised on the most high-profile and industry-shaping transactions in the healthcare sector. “Transactions in the late ‘80s led to my involvement in the two biggest transactions in 1995—the kickoff of the consolidation boom that we continue to see,” Frank tells The National Law Journal. In the past year, Frank represented Novartis in is $9.5 billion acquisition of The Medicines Company and Amgen in its $13.4 billion acquisition of rights to Celgene’s Otezla®.
As a thought leader on trends in global mergers and acquisitions, Frank is often sought for his perspective on important news of the day. On April 1, Frank was a guest on Bloomberg TV's “Bloomberg Surveillance,” where he discussed what dealmakers are seeing now and how the M&A market will move forward during the COVID-19 health crisis. To view the interview, click here.
To learn more about S&C’s Healthcare & Life Sciences Group, click here.